SMO and skin basal cell carcinoma: Current research targeting the Hh pathway is focused on SMO inhibitors, GANTs, and ligand/enzyme inhibitors, of which select inhibitors are FDA approved to treat BCC while others are still undergoing pre-clinical and clinical trials.